SG11202109545VA - Treatment employing anti-il-13r antibody or binding fragment thereof - Google Patents
Treatment employing anti-il-13r antibody or binding fragment thereofInfo
- Publication number
- SG11202109545VA SG11202109545VA SG11202109545VA SG11202109545VA SG 11202109545V A SG11202109545V A SG 11202109545VA SG 11202109545V A SG11202109545V A SG 11202109545VA SG 11202109545V A SG11202109545V A SG 11202109545VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- binding fragment
- treatment employing
- employing anti
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201902713S | 2019-03-26 | ||
SG10201905063R | 2019-06-03 | ||
SG10201907597W | 2019-08-16 | ||
PCT/SG2020/050170 WO2020197502A1 (en) | 2019-03-26 | 2020-03-26 | Treatment employing anti-il-13r antibody or binding fragment thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109545VA true SG11202109545VA (en) | 2021-10-28 |
Family
ID=70228774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109545V SG11202109545VA (en) | 2019-03-26 | 2020-03-26 | Treatment employing anti-il-13r antibody or binding fragment thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210277131A1 (en) |
EP (1) | EP3947457A1 (en) |
JP (1) | JP2022528324A (en) |
KR (1) | KR20210143788A (en) |
CN (1) | CN113677708A (en) |
AU (1) | AU2020247175A1 (en) |
CA (1) | CA3134495A1 (en) |
IL (1) | IL286603A (en) |
SG (1) | SG11202109545VA (en) |
WO (1) | WO2020197502A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048650A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2023048651A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
WO2023075700A1 (en) * | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
TW202333784A (en) * | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | Anti-il-13r antibody formulation |
TW202337905A (en) * | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | Glycosylated form of anti-il13r antibody |
WO2024043837A1 (en) * | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (en) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Device for centering and blocking a workpiece with a view to running it in using an expansion lapper. |
AU718899C (en) | 1995-10-23 | 2004-01-29 | Amrad Operations Pty. Limited | A novel haemopoietin receptor and genetic sequences encoding same |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
EP1449851A4 (en) | 2001-11-27 | 2005-11-16 | Mochida Pharm Co Ltd | ANTI-IL13 RECEPTOR alpha 1 NEUTRALIZING ANTIBODY |
CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
AR049390A1 (en) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME |
TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
PL2068921T3 (en) * | 2006-10-19 | 2014-12-31 | Csl Ltd | High affinity antibody antagonists of interleukin-13 receptor alpha 1 |
RU2009140134A (en) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | METHODS AND COMPOSITIONS FOR TREATMENT AND MONITORING TREATMENT OF IL-13 RELATED DISORDERS |
JP6063122B2 (en) | 2008-09-26 | 2017-01-18 | ユセベ ファルマ ソシエテ アノニム | Biological products |
US20200165347A1 (en) * | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
-
2020
- 2020-03-26 AU AU2020247175A patent/AU2020247175A1/en active Pending
- 2020-03-26 KR KR1020217032020A patent/KR20210143788A/en unknown
- 2020-03-26 US US17/272,243 patent/US20210277131A1/en active Pending
- 2020-03-26 SG SG11202109545V patent/SG11202109545VA/en unknown
- 2020-03-26 CN CN202080022235.4A patent/CN113677708A/en active Pending
- 2020-03-26 CA CA3134495A patent/CA3134495A1/en active Pending
- 2020-03-26 EP EP20717992.0A patent/EP3947457A1/en active Pending
- 2020-03-26 WO PCT/SG2020/050170 patent/WO2020197502A1/en active Search and Examination
- 2020-03-26 JP JP2021556845A patent/JP2022528324A/en active Pending
-
2021
- 2021-09-22 IL IL286603A patent/IL286603A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3947457A1 (en) | 2022-02-09 |
AU2020247175A1 (en) | 2021-10-14 |
WO2020197502A1 (en) | 2020-10-01 |
JP2022528324A (en) | 2022-06-10 |
US20210277131A1 (en) | 2021-09-09 |
KR20210143788A (en) | 2021-11-29 |
CN113677708A (en) | 2021-11-19 |
CA3134495A1 (en) | 2020-10-01 |
IL286603A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286603A (en) | Treatment employing anti-il-13r antibody or binding fragment thereof | |
IL263083A (en) | Single chain variable fragment cd3 binding proteins | |
IL277848A (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
GB201802338D0 (en) | Antigen binding proteins | |
IL287555A (en) | Binding molecules | |
ZA202108836B (en) | Anti-epha4 antibody | |
EP3269735A4 (en) | Anti-sclerostin antibody, antigen binding fragment and medical use thereof | |
IL291082A (en) | Anti-vsig4 antibody or antigen binding fragment and uses thereof | |
IL292799A (en) | Anti-siglec-9 antibody molecules | |
GB201901305D0 (en) | Specific binding molecules | |
IL304317A (en) | Tgf-beta-rii binding proteins | |
GB201919294D0 (en) | Antibodies or binding proteins | |
GB201900732D0 (en) | Antibodies | |
IL291364A (en) | Antigen binding proteins | |
IL288561A (en) | Anti-gal9 immune-inhibiting binding molecules | |
EP4038102A4 (en) | Biomarkers for anti-tigit antibody treatment | |
EP4051316A4 (en) | Antibodies for binding plasminogen | |
ZA202005023B (en) | L2a5 antibody or functional fragment thereof against tumour antigens | |
GB201906118D0 (en) | Anti-LAG-3 binding molecules | |
GB201911931D0 (en) | Anti-C7 antibody or antibody fragment | |
MX2018004228A (en) | Antibody specifically binding to erbb3 and use thereof. | |
GB201919286D0 (en) | Binding proteins | |
GB201914468D0 (en) | Binding Molecules | |
GB201912030D0 (en) | Binding molecules | |
GB201919062D0 (en) | Antibody |